Shares drop after the company announces pricing for its common stock offering. The clinical stage biopharma said that it is selling 25 million shares of common stock for $2.00 each. In addition, the ...

HOUSTON—May 23, 2019—Idera, Inc. (“Idera” or “the Company”), parent company of global B2B software productivity brands, today announced it will receive a new minority investment from Partners Group, a ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to ...

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for ...

HOUSTON, TX--(Marketwire - Oct 23, 2012) - Idera, a leading provider of application and server management solutions, today demonstrated its strong commitment to the PowerShell community by making its ...

Idera Pharmaceuticals Inc. (NASDAQ: IDRA) is focused on cancer and rare diseases, and it could be a what traders refer to as a three-bagger or four-bagger, if two analysts who made key calls in recent ...

Idera said on Monday that it has named Randy Jacops as CEO. Recently, Jacops worked as a venture partner at Valhalla Partners. Also, Josh Stephens has been hired as the company’s vice president of ...

The biopharma announced a massive public stock offering. The financing will add net proceeds of $46.8 million. While that's a sizable amount and will prove useful in efforts to further develop its ...

EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. “2021 represents a ...

Image source: Getty Images. Shares of Idera Pharmaceuticals (NASDAQ: IDRA) are down around 15% year to date. And that's a good thing, relatively speaking: The clinical-stage biotech's stock was down ...

EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the ...